Medacta Launches MiniMAX Hip Stem in U.S.

Medacta commenced U.S. launch of the MiniMAX™ anatomical cementless hip stem, suitable for minimally invasive anterior and posterior procedures.

The MiniMAX stem was launched in 2007 in Europe, and company research indicates a 97.5% survival rate at 5 years following revision and a 100% survival rate with aseptic loosening as a study...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us